EUR 2.36
(-0.84%)
Year | Total Liabilities | Total Liabilities Growth |
---|---|---|
2023 | 1.8 Million EUR | -14.26% |
2022 | 2.1 Million EUR | -0.38% |
2021 | 2.11 Million EUR | -1.55% |
2020 | 2.14 Million EUR | -12.29% |
2019 | 2.44 Million EUR | 10.11% |
2018 | 2.21 Million EUR | 26.25% |
2017 | 1.75 Million EUR | 0.0% |
Year | Total Liabilities | Total Liabilities Growth |
---|---|---|
2024 Q2 | 1.93 Million EUR | 0.0% |
2023 Q4 | 1.8 Million EUR | 0.0% |
2023 Q2 | 2.32 Million EUR | 0.0% |
2023 FY | 1.8 Million EUR | -14.26% |
2022 Q2 | 2.18 Million EUR | 0.0% |
2022 Q4 | 2.1 Million EUR | 0.0% |
2022 FY | 2.1 Million EUR | -0.38% |
2021 Q4 | 2.11 Million EUR | 0.0% |
2021 FY | 2.11 Million EUR | -1.55% |
2021 Q2 | 2.32 Million EUR | 0.0% |
2020 Q2 | 2.65 Million EUR | 0.0% |
2020 Q4 | 2.14 Million EUR | 0.0% |
2020 FY | 2.14 Million EUR | -12.29% |
2019 Q2 | 2.24 Million EUR | 0.0% |
2019 Q4 | 2.44 Million EUR | 0.0% |
2019 FY | 2.44 Million EUR | 10.11% |
2019 Q3 | 2.44 Million EUR | 8.72% |
2018 Q4 | 2.21 Million EUR | 0.0% |
2018 FY | 2.21 Million EUR | 26.25% |
2017 FY | 1.75 Million EUR | 0.0% |
Name | Total Liabilities | Total Liabilities Difference |
---|---|---|
Philogen S.p.A. | 28.68 Million EUR | 93.716% |
Ulisse Biomed S.p.A. | 4.69 Million EUR | 61.628% |